


Supplemental Table 1

Table I: qPCR Primers		
Gene	Forward Primer	Reverse Primer
GAPDH	CATGGCCTCCGTGTTCCCTA	TACTTGGCAGGTTTCTCCAGG
IFN γ	CAGCAACAGCAAGGCGAAAA	TCATTGAATGCTTGGCGCTG
IL-17a	TCTTTAACTCCCTTGGCGCA	TCAGGGTCTTCATTGCGGTG
IL-5	TGAGGCTTCCTGTCCCTACT	CCCCACGGACAGTTTGATT
IL-10	QuantiTect IL-10 Primer Assay (Qiagen catalog # QT00106169)	
iNOS	AAGATGGCCTGGAGGAATGC	TGCTGTGCTACAGTCCGAG
Arg1	QuantiTect Arg1 Primer Assay (Qiagen catalog #QT00134288)	
TNF α	ATGGCCTCCCTCATCAGT	TTTGCTACGACGTGGGCTAC


Table I: qPCR Primers. GAPDH served as housekeeping gene and was validated under all conditions tested. Each gene was tested in triplicated for each sample.

Supplemental Figure 1



Supplemental Figure 1: Anti-PD-1 antibody treatment does not substantially alter IFN-g and IL-17a gene expression in mice with cryptococcal lung infection. Infected C57BL/6 mice treated with either neutralizing anti-PD-1 or control antibody were evaluated for (A) IFN γ and (B) IL-17a gene expression by qPCR analysis using lung leukocytes obtained at 2 WOT (top panels) or 4 WOT (bottom panels). n=4-9/cohort assayed individually in two separate experiments; *=p<0.05 by unpaired Student *t* test.

Supplemental Figure 2



Supplemental Figure 2: Anti-PD-1 antibody treatment does not substantially alter lung lymphoid cell accumulation in the lungs of mice with cryptococcal lung infection. Infected C57BL/6 mice treated with either neutralizing anti-PD-1 or control antibody were evaluated for T and B cell accumulation at 2 WOT (top panels) or 4 WOT (bottom panels). $n=4-9$ /cohort assayed individually in two separate experiments; * $p<0.05$ by unpaired Student t test.